stocknews13h
3 Emerging Biotech Firms Pioneering Next-Gen Therapies
The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.
Arcus Biosciences (RCUS) Gets a Buy from Truist Financial
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today. The company’s shares ...
Zacks.com on MSN1d
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
Wall Street analysts forecast that Amicus Therapeutics (FOLD) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year increase of 190.9%. It is ...
Morgan Stanley Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average Target Price from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...